ArticlePharmaceutical research2025
Potential Transmembrane Proteins-transporters of Chelidonic Acid for its Intracellular Uptake: In Silico Simulation.
Article in Pharmaceutical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
introductionSmall molecules are biologically active organic compounds with molecular weight below 1 kDa. Their small size enables efficient transport across cell membranes and modulation of intracellular signaling, making them promising for drug development. Chelidonic acid (ChA) is a small molecule (184 Da) with a wide range of biological effects, but its transport mechanisms and molecular targets remain unknown. PURPOSE: The aim of this study is to identify a possibility of ChA uptake by human cells and to search for transporter proteins that may be involved in the intracellular trafficking of ChA using a combination of in silico and in vitro approaches.
methodsCo-culturing of human MCF-7 cells with ChA was conducted in vitro for 4 h and residual (not absorbed by cells) ChA concentration in solution was measured using HPLC. Candidate transporters were screened from databases. Molecular docking was performed with Autodock Vina, and molecular dynamics simulations were run for 50 ns using GROMACS to assess protein-ligand interactions. Statistical analysis used the R language with Newey-West estimator and Welch's t-test. HOLE and VMD were used for 3D-reconstruction and visualization of transport channels.
resultsMCF-7 cancer cells uptake ChA through one or several of the common cell transport proteins. Initial screening identified six transmembrane proteins, with further analysis pinpointing three candidates (GLUT3, SVCT1, URAT1) demonstrating structural and functional compatibility for ChA transport.
conclusionThe study contributes to the understanding of the pharmacokinetics and pharmacodynamics of ChA and provides the basis for the rational design of pharmaceutical substances based on it.
Indexed as
Identifiers
41062799What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.